gdc
Brain Cancer

Drugs for Brain Cancer & Acromegaly

Here are the financial support services available to patients receiving treatment for Brain Cancer.

Afinitor (everolimus) Tablets

Drug company: Novartis
800-245-5356

Afinitor is a kinase inhibitor used for the treatment of children and adults with tuberous sclerosis complex who have a brain tumor called subependymal giant-cell astrocytoma.

Novartis’ Patient Assistance NOW Oncology provides 2 financial assistance programs for patients using Afinitor:

Afinitor Co-Pay Card

Patients with private insurance will pay only $25 for a 28-day supply of Afinitor, and Novartis pays up to $15,000 per calendar year.

Novartis Patient Assistance Foundation

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Afinitor for free through the Novartis Patient Assistance Foundation. To be eligible, the patient must be a US citizen, and have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household. Eligible patients will receive Afinitor for free for 1 year, or until a prescription drug coverage becomes available to them.

Avastin (bevacizumab)

Drug company: Genentech
866-422-2377

Avastin is a VEGF-specific angiogenesis inhibitor used for the treatment of patients with glioblastoma multiforme, as a single agent for adults with progressive disease.

Genentech provides 2 financial assistance programs for patients using Avastin:

Genentech BioOncology Co-pay Card

Patients with private insurance are responsible for a $25 copay and up to $25,000 annually. There are no income requirements to participate in this program.

Genentech Access to Care Foundation

This foundation provides Avastin free of charge to uninsured and underinsured patients whose annual household income is less than $100,000. Avastin is also provided free of charge for patients whose annual household income is less than $150,000 and whose out-of-pocket prescription costs exceed 5% of their income (regardless of insurance).

Gleostine (lomustine)

Drug company: NextSource Biotechnology
855-457-8880

Gleostine is an alkylating drug used to treat patients with brain tumors (primary and metastatic) after appropriate surgery and/or radiotherapy.

NextSource Biotechnology provides 1 financial assistance program for patients using Gleostine.

NextSource Cares Patient Assistance Program

This program provides assistance related to coverage, prior authorization, and copay for Gleostine.

Gliadel Wafer (carmustine implant)

Drug company: Arbor Pharmaceuticals
866-516-4950

Gliadel Wafer is used for the treatment of patients with newly diagnosed high-grade malignant glioma in addition to surgery and radiation, and for patients with recurrent glioblastoma multiforme in addition to surgery.

Arbor Pharmaceuticals offers 1 financial assistance program for patients using Gliadel Wafer:

Arbor Patient Assistance Program

The Arbor Patient Assistance Program offers financial assistance for patients using Gliadel Wafer. For patients without insurance whose household income is 200% or less of the federal poverty guideline, Gliadel Wafer may be provided at no cost for patients receiving treatment as inpatients.

Temodar (temozolomide)

Drug company: Merck
800-727-5400

Temodar is an alkylating drug used, concomitantly with radiotherapy, and then as maintenance treatment, for the treatment of newly diagnosed patients with glioblastoma multiforme, as well as for the treatment of refractory anaplastic astrocytoma in patients whose disease progressed while using a drug regimen containing nitrosourea and Matulane.

Merck provides 1 financial assistance program for patients using Temodar:

Merck Patient Assistance Program

Uninsured patients who cannot afford to pay for Temodar and have an annual household income of $48,240 or less for individuals, $64,960 or less for couples, or $98,400 or less for a family of 4, may qualify to receive their medication for free.

Unituxin (dinutuximab)

Drug company: United Therapeutics
877-864-8437

Unituxin is a GD2-binding monoclonal antibody used in combination with granulocyte-macrophage colony-stimulating factor, interleukin-2, and 13-cis-retinoic acid for the treatment of pediatric patients with high-risk neuroblastoma who have had at least a partial response to previous therapy.

(United Therapeutics does not offer specific financial assistance programs for Unituxin.)

Benign Brain Tumors (Acromegaly)

Sandostatin LAR Depot (octreotide acetate for injectable suspension)

Drug company: Novartis
877-503-3377

Sandostatin LAR is a somatostatin analog used for the treatment of patients with acromegaly who have responded to and tolerated Sandostatin subcutaneous injection.

Novartis' Patient Assistance NOW Oncology provides 2 financial assistance programs for patients using Sandostatin LAR Depot:

Sandostatin LAR Depot Co-Pay Assistance Program

Patients with private insurance will pay up to $25 per month in copay and coinsurance. The program pays the remaining balance for Sandostatin LAR Depot until a yearly maximum of $15,000 is met.

Novartis Patient Assistance Foundation

Patients with limited or no public or private insurance may be able to receive Sandostatin LAR Depot for free. The patient must be a US citizen, and have an annual household income of up to $75,000 for 1 person and up to $25,000 more for each additional person. Eligible patients will receive Sandostatin LAR Depot for free for 1 year, or until they have prescription drug coverage.

Somatuline Depot (lanreotide) Injection

Drug company: Ipsen
866-435-5677

Somatuline Depot is a somatostatin analog used for long-term treatment of patients with acromegaly who have had an inadequate response to, or cannot be treated with, surgery and/or radiotherapy.

IPSEN CARES provides 2 financial assistance programs for patients using Somatuline Depot:

Somatuline Depot Virtual Copay Savings Program

Eligible, privately insured patients pay no more than $5 for Somatuline Depot for 12 months, for 13 injections, or for an annual maximum of $20,000 (whichever comes first). For patients with no insurance or whose insurance does not cover Somatuline Depot, the cost may be more than $5 per prescription, and the maximum benefit amount per prescription is $1,666.66, up to the annual maximum of $20,000 in total.

Somatuline Depot Patient Assistance Program

Eligible patients who are experiencing financial hardship, or have no insurance coverage, and meet specific medical criteria will receive Somatuline Depot for free.

Somavert (pegvisomant)

Drug company: Pfizer
844-989-7284

Somavert is a growth hormone receptor antagonist used for the treatment of patients with acromegaly who have had an inadequate response to surgery or radiation, or for patients who cannot use these therapies.

Pfizer offers 2 financial assistance programs for patients using Somavert:

Somavert Copay/Coinsurance Support Program

Privately insured, eligible patients may pay just a $5 monthly copayment while the card covers copay and coinsurance costs up to $20,000 annually.

Table. Drugs Prescribed for Brain Cancer & Acromegaly

  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services


    Drug name (generic name)
  • Gleostine (lomustine)
  • Drug company
  • NextSource Biotechnology
  • Indication
  • Brain tumor, primary and metastatic
  • Patient support services
  • NextSource Cares Patient Assistance Program
    855-457-8880

    Drug name (generic name)
  • Gliadel Wafer (carmustine implant)
  • Drug company
  • Arbor Pharmaceuticals
  • Indication
  • High-grade malignant glioma
    Recurrent glioblastoma multiforme
  • Patient support services
  • Arbor Patient Assistance Program
    866-516-4950

    Drug name (generic name)
  • Temodar (temozolomide)
  • Drug company
  • Merck
  • Indication
  • Newly diagnosed glioblastoma multiforme
    Refactory anaplastic astrocytoma
  • Patient support services
  • Merck Patient Assistance Program
    800-727-5400

    Drug name (generic name)
  • Unituxin (dinutuximab)
  • Drug company
  • United Therapeutics
  • Indication
  • High-risk neuroblastoma
  • Patient support services
  • (No specific program)
    877-864-8437




Last modified: April 16, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country